CV and mad panic behaviour

[ElwoodBlues1]

Sputnik, Sinovax, CoronaVac, Covaxin, AZ, Pfizer, Moderna, J&J and others have already issued about 3.2 Billion doses. I doubt any of them have much to fear, because it's highly unlikely Novavax exits any large scale roll out unscathed.

I'm quite cynical because the Novavax push appears to me to be more profit orientated than science based.

For reference, because they are selling vaccines for profit Novavax, Pfizer and Moderna are about 400% more expensive on average to the end user than AZ, Sinovax, Sputnik, Covaxin, etc., etc...

From a manufacturing perspective, it might be harder to make a mRNA hybrid (Influenza / Sars-CoV-2) vaccine, than it will be to formulate the same in viral vector(AZ) or protein sub-units(Novavax). I suspect in terms of Sars-CoV-2 it would be the mRNA vaccines that might lose out longer term.

PS: About 90% of vaccinations in Indonesia to date are Sinovax / CoronaVac, Indonesia they are not a big player in mRNA or Viral Vector. I wonder if the Indonesia Novavax push part of getting in on Australia's obligation under Covax to donate millions of doses of vaccine, whatever that vaccine may be? It feels like the sort of deal Scomo might do for some nuclear sub support in return!

Novavax will be marketed as Covovax in Indonesia and will be made by the Indian Pharma Serum Institute known as SII, I believe the WHO are expecting Novavax to donate to the Covax program for smaller countries with no money via their production with SII.
Greg Hunt has said no more AZ(Covaxin) in Aus after the last batch is produced and most of that is to be given away to pacific neighbors due to the poor takeup. Penny Wong wants it to go to Indonesia and wants the Government to continue to make it for poorer countries but last time I heard Hunt speak he said this batch will be the last.
Pfizer is the dominant player in the world and will dominate the non chinese market along with Moderna and make up 75% of that market. They will also be introducing new updated vaccines by mid 2022 and are banking on the fact everyone will want their newer tweaked vaccines rather than other companies older tech.
Dont disagree Pfizer and Moderna are money makers first and health providers 2nd and according to the Financial Times will be raking in 30-$54 billion which is double what the projected earnings were initially around 30 billion according to other analysts, Moderna no slouches either with 20-$38 billion...
Pfizer have also got in first for paediatric approval as well which will form a large part of their sales next year when many countries start approving vaccine jabs for kids...
Its going to be one way traffic business wise and thats a concern in terms of producing the best vaccines vs the best marketing and production programs which is what Pfizer have over the other vaccine providers.